OBJECTIVE： To systematically evaluate therapeutic efficacy and safety of pitavastatin comparison of atorvastatin in the treatment of primary hyperlipemia in Chinese adults， and to provide evidence-based reference for clinic. METHODS： Retrieved from The Cochrane Library， PubMed， Chinese Journal Full-text Database， Wanfang database， and manually search Google Scholar， Baidu academic search engine， randomized controlled trials （RCTs） about pitavastatin （trial group） vs. atorvastatin （control group） in the treatment of primary hyperlipemia in Chinese adults were collected. After literature screening， data extraction， quality evaluation of included studies with modified Jadad scale， Meta-analysis of the levels of total cholesterol （TC）， low density lipoprotein cholesterol （LDL-C）， triglyceride （TG） and high-density lipoprotein cholesterol （HDL-C）， response rate and the incidence of ADR was conducted by using Rev Man 5.3 statistical software. RESULTS： A total of 5 RCTs were included， involving 456 patients. Results of Meta-analysis showed that the decrease of TC level [MD＝0.09， 95％CI（0.01， 0.16），P＝0.03] in trial group was more better than control group， while the increase of HDL-C level [MD＝0.08， 95％CI（0.01， 0.14），P＝0.03] and the     decrease of the TG level [MD＝－0.13，95％CI（－0.20，       －0.06），P＝0.000 4] in trial group were worse than control group， with statistical significance. There was no statistical difference in the decrease of LDL-C[MD＝－0.01， 95％CI     （－0.13， 0.10），P＝0.84]， response rate [OR＝0.75， 95％CI（0.15， 3.66），P＝0.72] or the incidence of ADR [OR＝0.68， 95％CI（0.44， 1.05），P＝0.08] between 2 groups. CONCLUSIONS： Pitavastatin has better therapeutic efficacy in decreasing TC， but its therapeutic efficacy in decreasing LDL-C is similar to that of atorvastatin； its therapeutic efficacy in decreasing TG and increasing HDL-C is worse than that of atorvastatin. The safety of them is equivalent.